| |
Phase 3 MK-8527 Studies
|
| |
| |
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
https://clinicaltrials.gov/study/NCT07044297?intr=mk-8527%20011&viewType=Card&rank=1
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test results
Is a cisgender man, transgender woman (assigned male sex at birth), transgender man (assigned female sex at birth), or gender nonbinary person
Has had condomless receptive anal sex in the 12 months prior to screening (not including sex occurring in a mutually monogamous relationship) and has at least 1 of the following: receptive anal sex with 2 or more partners in the 3 months prior to screening (regardless of condom use), rectal or urethral gonorrhea or chlamydia or incident syphilis in the 6 months prior to screening, or any self-reported stimulant drug use with sex in the 3 months prior to screening
Weighs ≥35 kg
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
https://clinicaltrials.gov/study/NCT07071623?intr=mk-8527%20010&viewType=Card&rank=1
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
Is confirmed Human Immunodeficiency Virus (HIV)-uninfected based on negative HIV-1/HIV-2 test results
Has been sexually active (2 vaginal intercourse encounters with cisgender male individual(s) within the last 3 months)
Was assigned female sex at birth and is cisgender.
Weighs ≥35 kg
|
|
| |
| |
|
|
|
